Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR5A | P47898 | 12/20 | 0.71 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.40 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.38 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 2/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9908021 | 0.88 | HTR5A (0.55) | HTR5ACSNK2A2CSNK2B | |
| SCHEMBL9907670 | 0.85 | HTR5A (0.65) | HTR5ACSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL9907542 | 0.85 | HTR5A (0.72) | HTR5ANAPRT | |
| SCHEMBL9104920 | 0.83 | HTR5A (1.00) | HTR5A | |
| SCHEMBL9907689 | 0.82 | HTR5A (0.65) | HTR5ANAPRTCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL9907695 | 0.82 | HTR5A (0.65) | HTR5AAURKA | |
| SCHEMBL9907640 | 0.81 | HTR5A (0.71) | HTR5ACSNK2A2CSNK2BAURKAJAK2 | |
| SCHEMBL9907713 | 0.80 | CDH1 (0.51) | HTR5ACSNK2A2CSNK2BTSHR | |
| SCHEMBL9907505 | 0.80 | HTR5A (0.55) | HTR5ACSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL9907712 | 0.80 | CSNK2A2 (0.52) | HTR5ACSNK2A2CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853242-B2 | Nitrogenous-ring acylguanidine derivative | ASTELLAS PHARMA INC. (JP) | 2014-10-07 | — | — | US | disclosed |
| US-8853242-B2 | Nitrogenous-ring acylguanidine derivative | ASTELLAS PHARMA INC. (JP) | 2014-10-07 | — | — | US | disclosed |
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-07 | — | — | US | disclosed |
| WO-2011016504-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | アステラス製薬株式会社 (JP) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | HTR5A 1/4885NAPRT 1077/4885CSNK2A2 4132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.